Infinity Pharmaceuticals, Inc. (INFI) in Focus: Stock Moves 12% Higher

Infinity Pharmaceuticals, Inc.  INFI was a big mover last session, as the company saw its shares rise nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.14-$1.33 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Infinity Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP  is 0.00%.

Infinity Pharmaceuticals, Inc. Price and Consensus

Infinity Pharmaceuticals, Inc. Price and Consensus | Infinity Pharmaceuticals, Inc. Quote

A better-ranked stock in the Medical – Drugs industry is Corbus Pharmaceuticals Holdings, Inc. CRBP which currently carries a Zacks Rank #1 (Strong Buy). You can see  the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

Is INFI going up? Or down? Predict to see what others think:  Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we’re targeting

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report

Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research


comments powered by Disqus